Item 7.01 Regulation FD Disclosure.

On September 7, 2021, TransMedics Group, Inc. issued a press release announcing the receipt of the pre-market approval from the U.S. Food and Drug Administration for the Company's OCS Heart System for donors after brain death indication. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements. The press release attached as Exhibit 99.1 hereto contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the press release regarding these forward-looking statements.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits



Exhibit
  No.       Description

99.1          Press release issued by TransMedics Group, Inc. on September 7, 2021


104         The cover page from this Current Report on Form 8-K of TransMedics
            Group, Inc., formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses